The New York Times – Among critics of the federal prohibition of marijuana - a diverse and bipartisan group that includes both criminal justice reform advocates and Big Alcohol - the American Legion and its allies stand out.
TechCrunch – The company is the first wearable maker to get the green light from the NIH for the project, due in part to its compatibility with the two major mobile operating systems and the fact that its devices last several days on a charge.
Los Angeles Times – In a new study of patients with acute pain in their shoulders, arms, hips or legs, researchers found that a cocktail of two non-addictive, over-the-counter drugs relieved pain just as well as — and maybe just a little better than — a trio of opioid pain medications.
The Verge – Waymo reached an important milestone recently: since mid-October, the company has been operating its autonomous minivans on public roads in Arizona without a safety driver — or any human at all — behind the wheel.
STAT – The FDA plans on loosening many of the regulations surrounding genetic health risk tests, or GHRs. It’s a change of course for the agency, which in 2013 put a freeze on direct-to-consumer marketing of genetic tests for health conditions.
POLITICO – Patrick Soon-Shiong, the medical entrepreneur who has expanded his influence in Washington by cultivating close ties to both parties, has struggled to meet analysts’ expectations for sales of his GPS genetic test.
Nano and Other Emerging Chemical Technologies – On October 24, 2017, the Nanotechnology Industries Association (NIA) held a webinar on Safe by Design for Nanomaterials. The webinar was open to all actors interested in nanomaterials and their safe management throughout their lifecycle, using the principles of Safe by Design from the earliest development stages.
FierceBiotech – Sarepta has been signing a series of new R&D pacts since its controversial Duchenne muscular dystrophy (DMD) drug approval last fall, and today it’s penned a deal for one of the hottest research areas around: CRISPR.